In a previous blog post, we mentioned that we will be on the lookout for news relating to drug discovery for the coronavirus, in particular, anti-viral treatments. There has subsquently been news about Gilead's "remdesivir" showing promise along with a variety of anti-body treatments being developed by other companies.
When it comes to drug discovery, it is important to distinguish between "promise" and "proof". In the case of Gilead, the news was leaked from one of a number of trials that are yet to complete. It is not wise to draw conclusions that "promising indications" leaked from one arm of a trial in drug discovery will result in a better chance of achieving a meaningful outcome e.g. proof of effectiveness in clinical trials.You should take any such news with a pinch of salt. Unless a drug or vaccine has shown efficacy in the context of a Phase 3 trial and has been approved by the FDA the odds of that "promise turning into reality" are fairly slim.
Until we have solid proof of effective Phase 3 trial results and a variety of FDA approved anti-viral treatments, it will prove challenging to manage our way through this pandemic. Should Gilead's drug prove out to be effective, it still faces big challenges with respect to production and availability on a very large scale. Furthermore, it may prove to be effective in only certain type of cases and instances. What is needed is a toolbox of anti-viral drug treatments.